You will need to login first in order to enroll or view an activity. Login Here
23HT58930-31 Plasminogen Deficiency: An Ultra-rare, Multi-system Disease
July 21, 2023
5:00 PM Eastern, July 21, 2025
The estimated time to complete this activity is 60 minutes.
The purpose of this enduring material is to enable learners to gain knowledge of the diagnosis and management for plasminogen deficiency, and the treatment and support services available through the US HTC network.
This learning activity presents diagnostic and management considerations for plasminogen deficiency. Additionally, information is offered regarding the first FDA-approved treatment and the importance of the HTC as medical home for patients diagnosed with plasminogen deficiency.
This accredited continuing education activity is designed for multidisciplinary providers at Hemophilia Treatment Centers (HTCs) including physicians, advanced care providers, nurses, pharmacists, and other members of the multidisciplinary care team who might treat a patient presenting with plasminogen deficiency.
At the conclusion of this activity, the participants should be better able to:
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
No commercial support was received for this activity.
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
23HT58932-33 Plasminogen Deficiency: An Ultra-rare, Multi-system Disease
July 24, 2023
5:00 PM Eastern, July 24, 2025
The estimated time to complete this activity is 60 minutes.
The purpose of this enduring material is to support learners within the broader clinical community on the recognition of presenting symptoms of plasminogen deficiency and guidance regarding collaboration with specialized hematologists within the U.S. HTC Network for management and treatment.
This learning activity presents diagnostic and management considerations for plasminogen deficiency. Additionally, information is offered regarding the first FDA-approved treatment and the importance of the HTC as medical home for patients diagnosed with plasminogen deficiency.
This accredited continuing education activity is designed for physicians and other multidisciplinary staff including ophthalmology, dentistry, obstetrics/gynecology, neurosurgery, pediatrics, internal medicine, ENT/otolaryngology, pulmonology, nephrology/urology, gastroenterology, and advanced practice providers who might treat a patient presenting with plasminogen deficiency.
At the conclusion of this activity, the participants should be better able to:
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DENTAL PROFESSIONALS
The University of Nebraska Medical Center College of Dentistry Office of Continuing Education is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association designed to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry.
Concerns or complaints about CE providers may be directed to the provider or to ADA CERP at www.ada.org/cerp.
The College is a member of the American Dental Education Association and the Association for Continuing Dental Education.
The University of Nebraska Medical Center College of Dentistry Office of Continuing Education designates this activity for 1.0 continuing education credits.
No commercial support was received for this activity.
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
22HT57252 - Gene Therapy for Providers 101
October 14, 2022
5:00 PM Eastern, October 13, 2023
The estimated time to complete this enduring material is 45 minutes.
The purpose of this activity is to enable learners to develop basic knowledge of gene therapy for hemophilia, thereby enhancing learner competence to discuss gene therapy with patients who may benefit from this emerging treatment.
This learning activity provides basic education on hemophilia gene therapy, including the aims of gene therapy; the packaging, delivery, and activity of the replacement genes; and the means by which the replacement genes lead to production and/or availability of normal clotting factor in persons with hemophilia. The module will also review information that may be particularly important when discussing hemophilia gene therapy with patients, such as knowledgeable informed consent, outcomes data, and potential risks and benefits.
This accredited continuing education activity is designed for multidisciplinary providers at hemophilia treatment centers, including nurses, physicians, pharmacists, physical therapists, social workers, and genetic counselors providing care to persons with hemophilia A and hemophilia B.
At the conclusion of this activity, the participants should be better able to:
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PHARMACISTS (PharmDs/RPhs)
The University of Nebraska Medical Center designates this activity for 0.75 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. UAN # JA0000319-9999-22-018-H01-P
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.75 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
No commercial support was received for this activity.
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
22HT57253 - Gene Therapy for Providers 201
October 14, 2022
5:00 PM Eastern, October 13, 2023
The estimated time to complete this activity is 60 minutes.
The purpose of this activity is to enable HTC multidisciplinary staff and institutional stakeholders to gain knowledge on the steps necessary to prepare an institution to administer AAV-mediated gene therapy for hemophilia.
This learning activity is a process-oriented intermediate course that will guide HTC staff through the steps an institution must take to prepare to administer hemophilia gene therapy upon commercial availability of these products.
This accredited continuing education activity is designed for HTC multidisciplinary staff (physicians, physician assistants, nurses, nurse practitioners, physical therapists, social workers, pharmacists, geneticists, genetic counselors, infusion room staff) and institutional stakeholders (e.g., HTC administrators and directors, clinic and pharmacy billing staff, insurance coordinators).
At the conclusion of this activity, the participants should be better able to:
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia and Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PHARMACISTS (PharmDs/RPhs)
The University of Nebraska Medical Center designates this activity for 1 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. UAN # JA0000319-9999-22-019-H01-P
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hour. Nurses should only claim credit for the actual time spent participating in the activity.
No commercial support was received for this activity.
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
22HT57254 Gene Therapy for Providers 301
October 14, 2022
5:00 PM Eastern, October 13, 2023
The estimated time to complete this enduring material is 60 minutes.
The purpose of this activity is to enable HTC multidisciplinary staff and hospital staff to support patients and their families as they consider hemophilia gene therapy, including education of patients and families on basic concepts in hemophilia gene therapy; administrative preparedness for providers; and short- and long-term care demands.
This learning activity is a process-oriented intermediate course that will guide HTC staff through the steps an institution must take to prepare to administer hemophilia gene therapy upon commercial availability of these products.
This accredited continuing education activity is designed for physicians, physician assistants, nurses, nurse practitioners, physical therapists, social workers, pharmacists, and infusion room staff.
At the conclusion of this activity, the participants should be better able to:
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PHARMACISTS (PharmDs/RPhs)
The University of Nebraska Medical Center designates this activity for 1 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. UAN # JA0000319-9999-22-020-H01-P
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hour. Nurses should only claim credit for the actual time spent participating in the activity.
No commercial support was received for this activity.
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
21HT50146 Hereditary Hemorrhagic Telangiectasia: Right Under Your Nose
June 1, 2022
5:00 PM Eastern, May 31, 2024
The estimated time to complete this activity is 60 minutes.
This online learning activity aims to enable the learner to gain knowledge and expertise regarding hereditary hemorrhagic telangiectasia (HHT), including inheritance and pathophysiology, screening guidelines, management, and the importance of the multidisciplinary approach in caring for these patients.
This online learning activity provides a detailed introduction to hereditary hemorrhagic telangiectasia (HHT) appropriate for an audience of multidisciplinary health care providers involved in the team-based care of patients with HHT. This overview includes information on the genetic inheritance and pathophysiology of HHT as well as the widely-used Curaçao diagnostic criteria to determine if a person has HHT, consensus screening guidelines for HHT management, and an explanation of the importance of a multidisciplinary approach to care of patients with HHT. This activity incorporates case scenarios and interactive questions to encourage active learning through application of the content.
This accredited continuing education activity is designed for physicians, physician assistants, nurse practitioners, nurses, and other multidisciplinary team members who care for patients with hereditary hemorrhagic telangiectasia.
At the conclusion of this activity, the participants should be better able to:
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hours. This activity is provided for 0.15 contact hours related to pharmacotherapeutic content. Nurses should only claim credit for the actual time spent participating in the activity.
No commercial support was received for this activity.
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
22HT54278 - Advance Care Planning and Advance Directives
August 29, 2022
5:00 PM Eastern, August 29, 2024
The estimated time to complete this activity is 60 minutes.
The activity aims to enable the learner to understand the process of advance care planning, the associated healthcare decision making document aids, and additional resources to assure patient's wishes are elicited and documented in a meaningful manner.
This learning activity provides education on the development of a robust Advance Care Planning (ACP) program and covers the goals, barriers, and enabling strategies to implement an ACP program with patients. This module also offers many ACP resource documents, patient decision aids, and communication tools and techniques for how to facilitate these ACP conversations with patients to honor their wishes when it comes to their goals of care during this period of life.
The content level of this activity is intermediate.
This accredited continuing education activity is designed for physicians, advance practice clinicians, social workers, and nurses caring for patients with bleeding disorders. This activity will additionally target care managers, spiritual care specialists, and other multidisciplinary providers involved in caring for patients with bleeding disorders.
At the conclusion of this activity, the participants should be better able to:
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1.0? AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hour(s). Nurses should only claim credit for the actual time spent participating in the activity.
SOCIAL WORKERS
As a Jointly Accredited Organization, University of Nebraska Medical Center is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.0 general continuing education credits.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
21HT50199 - MASAC Pain Initiative Task Force Pain Management Guidelines for Bleeding Disorders
January 10, 2022
5:00 PM Eastern, December 15, 2023
The estimated time to complete this activity is 120 minutes.
The content level of this activity is intermediate.
The purpose of this enduring material is to enable the learner to gain knowledge on the opioid guidance document published in early 2020 by the Medical and Scientific Advisory Council (or MASAC).
In this module, there are several aspects of pain management that will be addressed. Foremost is to familiarize you with the MASAC opioid guidance document established in 2020. In addition, we will describe the importance of standardized assessment of pain. This activity will help you to determine goals for pain management and how the roles of each team member can help incorporate non-pharmacological pain management options. Lastly, opioid issues including when and how to start opioids for pain management and monitoring systems that will assist you will be covered in the modules. To enhance the learning, case studies will be examined.
This enduring material is intended for physicians, physician assistants, nurse practitioners, nurses, social workers, physical therapists, and other interested members of the bleeding disorder comprehensive care team.
At the conclusion of this enduring material, the participants should be better able to:
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 2.0 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
As a Jointly Accredited Organization, University of Nebraska Medical Center is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. University of Nebraska Medical Center maintains responsibility for this course. Social workers completing this course receive 2 continuing education credits.
PHYSICAL THERAPISTS
This activity is approved for physical therapy continuing education units (CEUs) through the California Physical Therapy Association (CPTA) (Approved for 0.2 CEUs by CPTA #22-584). While many states recognize continuing education credits from CPTA, please verify with your state Board that these credits are acceptable in your state. To learn more about CPTA, visit https://www.ccapta.org.
No commercial support was received for this activity. Supported by an educational grant from the National Hemophilia Foundation.
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
The Partners in Bleeding Disorders Education Program is supported by educational grants from Takeda Pharmaceuticals U.S.A., Inc; Genentech, a member of the Roche Group; National Bleeding Disorders Foundation (NBDF); and the Hemophilia Alliance.
Copyright © 2023 Indiana Hemophilia & Thrombosis Center. All rights reserved. Privacy Policy | Travel Policy | Terms of Service Credits